News
06-04-2011, 02:50 AM
In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.
More... (http://www.news-medical.net/news/20110604/Results-from-HSPPC-96-Phase-2-study-against-recurrent-gliobastoma-presented-at-ASCO-2011.aspx)
More... (http://www.news-medical.net/news/20110604/Results-from-HSPPC-96-Phase-2-study-against-recurrent-gliobastoma-presented-at-ASCO-2011.aspx)